Table 4.

Adjuvant chemotherapy regimens and relapses in 48 patients with metaplastic breast cancer

Chemotherapy regimen	Number	Patient outcome
Cyclophosphamide, methotrexate and fluorouracil	7	Seven relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide	7	Two relapse-free at 45 and 57 months. One alive and well at 62 months after a local recurrence. Two progressed while receiving adjuvant therapy. Two relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide to taxane, paclitaxel/cisplatin/carboplatin	9	Five relapse-free at 30, 53, 66, 69 and 101 months respectively. Four relapsed.
Taxane/paclitaxel, anthracyclines and cyclophosphamide	18	Eight relapse-free at 55, 64, 75, 91, 108, 110, 123 and 156 months respectively. Ten relapsed.
Taxane, anthracyclines and cyclophosphamidein combination with cisplatin/capecitabine	4	Three alive and well at 17, 25 and 39 months after a local recurrence. One alive at 45 months before a local recurrence, alive at 20 months after distant metastasis.
Paclitaxel, anthracyclines and cyclophosphamidein combination with capecitabine/vinorelbine	3	Three alive at 24, 29 and 41 months before a local recurrence, alive at 15, 18 and 25 months after distant metastasis.